Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer

Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer

Abstract Background Hu-rhEGF-rP64k/Mont is a biotechnology product for the treatment of advanced non-small cell lung cancer (NSCLC). The vaccine induces a neutralizing antibody-mediated immune response, against the normal circulating self-protein antigen epidermal growth factor (EGF), which prevents...

Full description

Bibliographic Details
Main Authors: Puyuan Xing, Hongyu Wang, Sheng Yang, Xiaohong Han, Yan Sun, Yuankai Shi
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Immunology
Subjects:
Cancer vaccine
Lung cancer
Clinical study
Online Access:http://link.springer.com/article/10.1186/s12865-018-0249-9

Internet

http://link.springer.com/article/10.1186/s12865-018-0249-9

Similar Items